VITAMIN C AND ASCORBIC ACID
Dr. Robert Cathcart, MD, has treated over 20,000 patients worldwide with dosages of ascorbate many orders of magnitude higher than the U.S. RDA. We have asked Dr. Cathcart to comment on the incidence of Cancer and Arthritis among his patients. (Dr. Cathcart has previously commented that heart disease is "unknown" in his practice.)
Dr. Cathcart's preliminary response:
Clinically, I have seen no evidence of DNA damage. I have seen a few cancer patients who have taken vitamin C fairly regularly for a number of years but there are not many and in the large number of patients I have put on large doses of C there seems to be a smaller than normal number who have developed cancer. I know that follow-up in a private practice is not perfect but I have not seen a single autoimmune disease such as rheumatoid arthritis develop while the patient was on large doses of ascorbic acid.What is very remarkable is that I cannot recall a single patient who had a good heart before starting large doses of ascorbic acid who ever developed a heart attack after being on ascorbic acid. This would seem to be true of all of the arteriosclerotic problems. I actually find this hard to believe but a least in my limited experience, it is true. On the subject of cancer: there is a remarkable lack of new cancer developing in AIDS patients after they have been on the large doses of ascorbic acid in combination with my whole nutritional program for AIDS. [Robert Cathcart, III, MD, April 10, 1998]
Natural vs. synthetic ascorbic acid
¨¨¨Natural and synthetic L-ascorbic acid are chemically identical and there are no known differences in their biological activity. The possibility that the bioavailability of L-ascorbic acid from natural sources might differ from that of synthetic ascorbic acid was investigated in at least two human studies and no clinically significant differences were observed. A study of 12 males (6 smokers and 6 nonsmokers) found the bioavailability of synthetic ascorbic acid (powder administered in water) to be slightly superior to that of orange juice, based on blood levels of ascorbic acid, and not different based on ascorbic acid in leukocytes (white blood cells) (1). A study in 68 male nonsmokers found that ascorbic acid consumed as cooked broccoli, orange juice, orange slices, and synthetic ascorbic acid tablets are equally bioavailable, as measured by plasma ascorbic acid levels (2,3).
Different forms of ascorbic acid (powders, tablets, etc.)
The gastrointestinal absorption of ascorbic acid occurs through an active transport process, as well as through passive diffusion. At low gastrointestinal concentrations of ascorbic acid active transport predominates, while at high gastrointestinal concentrations active transport becomes saturated, leaving only passive diffusion. In theory, slowing down the rate of stomach emptying (e.g., by taking ascorbic acid with food or taking a slow-release form of ascorbic acid) should increase its absorption. While the bioavailability of ascorbic acid appears equivalent whether it is in the form of powder, chewable tablets, or non-chewable tablets, the bioavailability of ascorbic acid from slow-release preparations is less certain.
A study of 3 men and 1 woman found 1 gram of ascorbic acid to be equally well absorbed from solution, tablets, and chewable tablets, but the absorption from a timed-release capsule was 50% lower. Absorption was assessed by measuring urinary excretion of ascorbic acid after an IV dose of ascorbic acid and comparing it to urinary excretions after the oral dosage forms (4). A more recent study examined the plasma levels of ascorbic acid in 59 male smokers supplemented for 2 months with either 500 mg/day of slow-release ascorbic acid, 500 mg/day of plain ascorbic acid, or a placebo. After 2 months of supplementation no significant differences in plasma ascorbic acid levels between the slow-release and plain ascorbic acid groups were found (5).
Journal of Orthomolecular Medicine, 1999; Vol 14 (3): 143-56.
Ascorbic Acid and Some Other Modern Analogs of the Germ Theory
John T. A.
Radiation Studies, Box 351310
University of Washington
Seattle, WA 98195
On the Cost of Traditional Opposition to Modernization in Clinical Medicine
The Modus of Opposition
There is an almost universally held view that medicine is and should be a prestigious profession. Sadly, in recent decades, significant erosion of this view has occurred. The general nature of the erosion and other published laments are cited here. There is preponderant agreement among scientists and the lay public that medicine has an obligation to know what "is known" (ie, that given modalities have been reported in the literature by competent authors to be far superior to corresponding treatments of choice, but their adoption has been opposed without reason). Work by Hoffer and Pauling led to a fundamental principle of orthomolecular medicine which involves the adjustment of levels of molecules that are normally in the body which can both prevent and cure disease with little toxicity or side effects compared to xenobiotic drugs. The theme detailed in this paper was developed by Pauling, Klenner (p.63), Shute (pp. 77-83, Appendices), Coca (pp.185-9) and others (hereinafter called Pauling et al) who: (1) cite evidence they claim proves that virtually every disease can be treated with far greater safety and efficacy[5,6] ie, with less Morbidity & Mortality (M&M) and far less cost, with rejected modalities (frequently orthomolecular) alone, or adjunctively to standard care in some cases; (2) report that mainstream medicine has either ignored or actively opposed adoption of these modalities by falsely condemning them without investigation or proper clinical trial; (3) claim that these actions have doomed most US citizens to disease filled lives and early deaths after enormous suffering and expense from invasive outmoded inefficacious "treatments of choice"; (4) state the opposition comes from self-appointed but highly influential "authorities" (often identified) who most frequently are not practicing physicians at all, have never studied or used, and do not understand the modalities they condemn, such as orthomolecular AA (ascorbic acid or ascorbate), or even the genetic basis for megavitamin therapy (Ch.11) or that the strength of one's convictions is no criterion of their validity; and (5) named true experts from mainstream whose endorsement of rejected modalities was also ignored (ie, AA in surgery for wound strength and buffy coat, and in myocardial infarct for buffy coat, etc; high vitamin E for phlebitis, other thromboses, hemolysis, etc). These rejected modalities are all analogs of the germ theory.
Germ Theory Analogs
History insists medicine has shown the same characteristic behavior, denying that blood circulated in the body, denying the germ theory, denying the role of ascorbic acid and other "analogs of the germ theory" (ie, basic facts readily proven from the literature to be of great importance and subsequently adopted although initially vigorously opposed at enormous cost in M&M). There is evidence from the life of Westin Price, PhD, DDS, impressive scientist and coworker of Charles Mayo, MD, that some senior physicians in large city hospitals still had not accepted the germ theory as recently as 1920. We study here the evidence of Pauling et al using the modern analogs, the first of which is AA (although commonly called "vitamin C", we show it is not a vitamin). If it is true that mainstream medicine is chronically unable to modernize (ie, impartially evaluate new modalities in a timely way) for which Pauling et al make a compelling case, there must be extenuating circumstances. Certainly, the vast majority of mainstream practicing clinicians are highly educated and motivated, hard working people (no one works harder) who would favor better modalities even if "unprofitable" but, it appears, are losing well deserved respect through no fault of their own. Clinicians: (1) will not have had time to read the medical literature because of the "size problem" discussed below; and (2) will have heard entirely erroneous opinions from high "experts" on the matters of interest here. Due to peer pressure, time pressure, mindset, etc, in the self-regulated medical profession, the new modalities continue to be ignored. There is a sad difference in this regard between the communities of physics and clinical medicine. When something new is tentatively announced in physics, every physicist in the world is interested and wants to know about it. However, in medicine it seems that essentially no one wants to hear about the germ theory analogs.
The Literature Size Problem (an extenuating circumstance)
Medical science literature has become essentially inaccessible because of its size. At the University of Washington, the Health Sciences Library receives over 40 million new pages per decade from the journals to which it subscribes. Most of this material is both excellent and relevant to clinical medicine. It isn't possible to turn this many pages in a decade. No clinician (or even researcher) could possibly find the time to read 1% (40,000 pages/year) of the flood. Thus, we are all ignorant of the greatest findings. It might be stated: there is no area of human endeavor where ignorance (of what is known) is growing as rapidly as in clinical medicine.
What can be Done?
Relevant history of AA and some other related analogs are reviewed here with descriptions of the immense harm from their neglect. It has been estimated that the total annual U.S. health care cost including both private and public funds exceeds $1 Trillion (ie, over one sixth of the national debt) or $4000/capita. In spite of this largess, it is widely stated that these 273 million citizens suffer more invasive, toxic, ineffective life-shortening therapies than any comparable group in history. The question is considered of whether the self-regulating medical establishment can be allowed to continue ignoring new modalities on the basis of ignorant bias of an influential few whose style seems to be "condemnation without investigation" (as per Pauling's meticulous expose' of many cases). An alternative might be the creation of a committee (shielded from influence) requiring that advocates of "analogs" be allowed to demonstrate, for example, that AA will cure: most viral infections (including acute hepatitis and polio); most cancer (with glycemic control); most otherwise lethal intoxications, snakebites, etc; etc; and that severe penalties be imposed for: (1) misleading mainstream medicine or the public re true value of the "analogs", thereby greatly increasing M&M and care cost (literally bankrupting the nation and killing the people); or (2) influencing editorial policy of medical journals against manuscripts that report benefits of "unprofitable" modalities; etc.
A Preview of
Four Major "Analogs"
Recall from the first paragraph above, Pauling et al state that fundamental orthomolecular modalities such as AA, vitamin E (E), coenzyme Q10 (CoQ10) and glycemic control (or unrefined diet) have all been proven to enhance health and longevity and have much lower cost and greater efficacy for most diseases than corresponding conventional care (for details, see later sections and references cited). The "Mammals" section below seeks to clarify widespread misconceptions re AA, a modality of central interest in this paragraph and most of the others. But, before we get into that, we wish to show that opposing the adoptions of these four modalities is not "saving" people from quackish nostrums, but dooming them to standard care M&M (which most people can only escape by the disease prevention provided by these adoptions). People whose intake provides the RDA for AA (60 mg/d) and E (10 mg/d), the average diet's CoQ10, and 50% of calories in the US refined diet: (1) will have a body AA pool ~1.5 g; this could last a month if unperturbed, but can fall to 0.5 g in one day of pain, fear, or other stress; at that point the WBC (white blood cells or buffy coat) level is scorbutic, resistance to infections and ability to heal are very depressed, a typical finding in heart attack and non-elective surgery patients; (2) will all be E deficient (because the US polyunsaturated fatty acid intake is several fold in excess of 1 g/mg E) with increased susceptibility for rapid aging, cancer, heart disease, hemolysis, stroke and other thrombotic accidents; the <10% hemolysis of "normal healthy" people on the hydrogen peroxide test of RBC is due to E deficiency and disappears with 200 IU E/d; (3) the ~20 mg CoQ10 in the average diet becomes inadequate since endogenous synthesis declines after age 20, and brain levels halve between 45 and 70, worsening or causing many disorders and increasing risk of stroke8; and (4) risk and severity of every major disease are increased by the refined diet.[7,9]
Normal Mammals and Stress.
As Pauling et al reported, ignorant self-appointed "authorities" have conveyed to clinician and lay readers alike false and dangerous notions such as AA doses much above a gram are innately dangerous and wasteful because white blood cells (WBC) are saturated, etc. When viewed in the perspective of the Pauling et al expose' and the papers to which they lead, doesn't it appear that rejection of the analogs (AA alone!) was responsible for millions of deaths and trillions of dollars? Correction of the three falsities above is given briefly in three numbered statements here (and in detail in the rest of this and later sections): (1) the mammals discussion here, other sections below, and many references cited explain why large doses, even >200 g/d AA have given great benefit in all patients (rapid healing, curing most "incurable" infections including polio, etc) except humans with genetic susceptibility to hemolysis (see below); (2) spilling AA in the urine is viewed as wasteful by the "authorities" who seem to be unaware that mammalian evolution selected plasma AA levels that provide normal healing, resistance to disease and stress, etc, and which, even in the unstressed state are well above the renal threshold (~1 mg%), so continually spilling AA in the urine is the price that must be paid for these qualities by both normal (AA synthesizing) mammals and others like humans who must supplement (properly) to do so; and (3) thus, for animals and humans using AA correctly, WBC AA (usually measured as buffy coat AA) does not "saturate" but is pumped up to a large multiple of the plasma level that, as stated in (2) above, is always higher than renal threshold.
There is one simple way to gain much understanding of the true kinetics of AA and the reasons for the confusion that dominates modern medicine re this small but extremely important molecule. First, we cite a widely accepted fact that, among the ~4000 mammals, only four, humans, the other primates, the guinea pig and a fruit eating bat are known to have lost, through a genetic defect, the ability to synthesize AA, and must get it from exogenous supply. They are considered "abnormal" in this defect that has strongly influenced human history (military campaigns, especially naval, etc). It is believed all other mammals synthesize AA copiously from glucose in the liver and that AA has a number of functions that are very necessary for health and survival, especially in stress. Now, we consider what happens in stressed "normal" mammals and what role AA plays. A normal mammal (goat, dog, cat, etc) can be stressed in any of several ways (by disease, intoxication, pain, rage, etc): the first two can occur in a normoglycemic state such as a rat given aspirin. Sixty years ago, it was shown that, in response to aspirin, barbiturates or other intoxicants, rats would increase their synthesis of AA 100 to 1000 times and excrete urine AA far in excess of their total body stores daily. It has been inferred that the great elevations of plasma AA necessary to excrete such quantities in the urine, accelerate healing, etc, is many times the renal threshold (possibly >100) (p.109). If prolonged for a day or more, such plasma AA rises result in corresponding increases of AA in WBC and extreme stimulation of CMI (cell mediated immunity) ability to resist disease by destroying viral and other pathogens and some tumors.[13-26]
To provide the vital needs of a special metabolic pathway called the HMP shunt (or the "pentose pathway"), AA is required at very high levels in WBC. The HMP shunt: (1) supplies ribose needed to copy DNA in cell division (when, for example, the disease antigen is sensed and cytotoxic T-cells need to multiply to destroy the pathogen); and (2) helps regenerate the toxic chemicals necessary for use in phagocytic cells (to destroy pathogens they ingest (phagocytize). The rate of the HMP shunt increases about 700% as plasma AA rises from 0.7 mg% (a typical human value) to 140 mg% (~100 times the renal threshold) and stimulates WBC functions correspondingly. There can be no doubt that this marked increase in CMI including increased interferon production at high AA must have been developed during evolution in response to infective challenge.
Humans and Stress.
In the human many AA functions (ie, the renal thresholds for AA, etc) are the same as in normal mammals; thus, one realizes the system "expects" the adrenal response to infective or trauma stress to be supported by AA synthesis from the liver which does not occur, leaving every sick or surgical patient in CMI anergy (WBC suppression). This dangerous fall of WBC AA to scorbutic levels within 12 hours after stress was reported in 31 consecutive heart attack patients. The expected striking increase of CMI at extremely elevated plasma AA and prompt ability to cure polio, viral encephalitis, acute hepatitis, etc, in a few days has been also reported repeatedly by numerous investigators using intravenous and oral AA in humans which replaces the missing liver response.[12,14,16,18-20] Thus, from consideration of the stress response in normal mammals, we see that AA is not a vitamin (a nutrient needed in minute quantities) but a molecule with many functions that can require from ten to >100 g/d to obtain the benefits gained by normal mammals (Ch.4) and thus, humans must greatly augment body AA stores during disease or other stress. Stone summarizes National Research Council AA RDA's for three defective mammals, human, monkey, and guinea pig (in mg/kg body weight) respectively as 1, 55, and up to 167 (depending upon guinea pig diet)! If a 60 kg human desires a health status as high as the monkey or guinea pig, it appears the RDA should be between 3 and 10 g/d. In the same source, Stone tells us that Klenner, Pauling, Dr Albert Szent-Gyorgyi (Nobel Prize in Medicine for AA research), and other notables all agreed with him or called for even higher RDA's.
Now, we return to the educated human who wishes to supplement AA to simulate the missing liver synthesis. It is not trivial because, in the stressed normal mammal, the WBC are continuously (possibly days or weeks) in blood that contains many times the usual level of AA. It was shown in 1961 that WBC (which normally "pump up" their internal AA levels to ~50 times the existing plasma level) require about 20 hours incubation in grossly elevated AA to pump up to ~50 times that new level. This shows that WBC don't "saturate", as has been suggested by others to occur at very low AA intake. It is a remarkable fact that this amplification of WBC AA occurs, but unfortunate for humans that it takes so long (~1 d) to adjust. It is trivial to elevate plasma AA levels to ~4 mg/dL as described by Lewin (p.151) if a human adult takes oral AA 1 g/hr thus permitting exposure of the CMI to sustained elevations. Although very high AA levels have been shown by many investigators[2,18-22] to enhance CMI and provide rapid recovery, truly sustained AA elevations in plasma require constant oral AA dosing during acute disease. Robert F. Cathcart, MD, world famous for his work in orthopedic surgery at Stanford, developed the AA bowel tolerance protocol, so effective for infectious diseases, and gives much emphasis to this need. For this reason, physicians such as Klenner and Cathcart, who were successful in treating polio, viral encephalitis, hepatitis, AIDS, etc, with intravenous ascorbate (IVC) drip, also always gave oral AA around the clock (time release AA tablets for outpatients in sleep).
Hemolysis: AA and Vitamin E
It is important to anticipate hemolysis and prevent it by increasing E intake with high AA. However, without mention of E, Klenner and Cathcart report treating over 30,000 patients with multigram doses of AA for over 4 decades without a single report of serious side effects. In a standard in vitro test of hemolytic tendency of RBC using hydrogen peroxide, a "normal" (no supplemental E) human's value (~9%) may typically be increased by half (to ~14%) one day after ingesting 1 g AA (Mengel pvt commun). Why is hemolysis not seen in normal subjects at high AA? The following hypothesis is offered to explain: these RBC, the ~9% that disintegrate under oxidative stress of the test, are the oldest, ie, nearest to the 120 day nominal life span; the increased hemolysis observed after (small) AA intake is a toxic effect due to DHA (AA oxidized in the RBC; 75% of blood DHA is in RBC); but, if large doses of AA, ie, multigram, oral or IV are given, the redox potential (found using the ratio AA/DHA in the Nernst equation) is so reducing that this ratio remains high, and DHA in RBC is too low to cause hemolysis. Thus, the safety and efficacy of AA have been proven in many thousands of patients (who have no genetic susceptibility to hemolysis) and reported in detail by Klenner[2,18,20], Hoffer[5,6], and Cathcart[14,15].
However, in subjects with these lytic tendencies, such as G-6-PD (glucose-6-phosphate dehydrogenase) deficiency, sickle-cell anemia and beta-thalassemia, this RBC fragility must be addressed. Individuals with this defect are at increased risk of hemolysis from various drugs, infections and other stresses. Improved hematological parameters following long term supplementation of E at 800 IU/d is reported. Use of AA should still be approached with great caution and only with RBC hemolysis monitoring. Without these measures, there has been one report of a death, and several cases of hemolytic emergencies associated with large doses of AA.[30,31] It has been recognized for almost 50 years that vitamin E protects red blood cells from hemolysis.32 And, Chen showed that supplemental vitamin E strongly diminished red blood cell hemolysis in rats given AA, with the protection increasing in a dose-dependent way with the level of E. Thus it seems prudent to supplement E when taking multigram doses of AA.
Glycemic Control as a Modality
Almost 2000 years ago in the time of Galen, it was observed that tumors grew poorly or not at all in underfed animals. As a result of a simple theory called the "glucose-ascorbate antagonism" and strongly supporting studies in both humans and animals, it now appears certain that CMI works best when blood sugar is low.[23,24,34] Of course, one doesn't want it too low... humans become unconscious (not necessarily harmful) below 40 mg%, brain damage is reported to occur below 20 mg%, but CMI is reported to work well down to ~10 mg %. In frequent or prolonged hypoglycemia, care must be taken re cortisol rise (and the associated lympholytic effects) that differ greatly among subjects and conditions. Cancer, infections and other diseases (CVD, etc) have lower incidence (and heal more rapidly if AA is adequate) at the low blood sugar levels seen on primitive diets, ie, 50 to 90 mg%[35,36] Deficiency in trivalent Cr in US soil and diet has long been said to be a cause of impaired glucose tolerance and disease. Some questions have been raised about the safety of CrPicolinate as a Cr supplement.
Stress and AA
Rapid response of the adrenals in emergency is vital to mammalian survival and its mediator, "fight or flight". It is well known that the highest AA concentration in the adult human (~70 times plasma level) occurs in the adrenal cortex (where it is used as an electron donor in myriad syntheses) but can be depleted rapidly in any severe stress (such as injury, intoxication, fear, etc). This can occur in hours in humans; but, in normal mammals, liver production of AA can increase over 100 fold synchronous with stress onset replacing the adrenal stores (maintaining readiness for the next emergency, improving stamina, rate of healing, etc, and resistance to stress and disease and bolstering other protective and repair processes). Even when not in stress, normal (AA synthesizing) mammals such as the dog have plasma AA levels higher than the renal threshold and void AA in the urine ~1 g/d. Monkeys (non-synthesizers) given the human equivalent of 4 g AA/d were far more resistant to extreme cold exposure than monkeys given the equivalent of 300 mg daily. In a study of 100 elderly hospital patients with adrenal insufficiency (and other disorders as primary), administration of 0.5 g AA resulted in immediate return of adrenal function.
Allergy and AA
Anaphylactic shock and AA
Since the 1930's when AA first became available, many researchers have studied anaphylaxis and showed that AA could prevent death and even the symptoms of shock in a sensitized animal. Their results demonstrated a dose dependent protection that was reproducible for a given species and allergen type and dose. For example in guinea pigs sensitized to horse plasma 50 mg prevented shock symptoms and death whereas 20 mg only delayed death.40 Extrapolation to a 70 Kg human would suggest that ~15 g might be required for protection against symptoms and death.
For 40 years, there have been theory and evidence that allergies are stress diseases that can be prevented, and frequently cured by nutritional therapy including large intakes of AA, pyridoxine (vit B-6) and pantothenate (vit. B-5)[41,42]. It has long been known that urine and plasma levels of ascorbic acid are low during seasonal or other exacerbations of allergic rhinitis and in humans (for over 25 years and 8 years earlier in guinea pigs), that AA antagonizes the airway constriction effect of histamine.
Allergy and Disease
Arthur F. Coca, MD, founder and first editor of the Journal of Immunology, Medical Director of Lederle Labs for 17 years, namer of atopy, etc, demonstrated that (mainly) noninfectious disorders of virtually every body system could be caused by allergies to foods, inhalants, etc, and could be eliminated by avoidance of the allergens. His disease list included many "incurables" treated with great expense and morbidity by mainstream medicine. He developed the simple "pulse test" for allergen identification. As per pp.185-9: although the findings of other great allergists (W. Vaughan 1927; H.J. Rinkel 1944; etc) and internists (Walter Alvarez of Mayo) directly supported his work, it was rejected without trial by the same arrogance and ignorance ensconced in the seats of power that have suppressed the other "analogs". Three mechanisms uniting these diseases as allergic dysautonomias were explained by Ely in 1978 using one of the clues related to the biochemistry of schizophrenia uncovered by Hoffer. It has been widely reported that the psychosis of institutionalized persons quickly (~4 days) recovers on water fast (allergen avoidance) (Well Mind Assn Newsletters, Jun 1982, Oct 1989, Dec 1989, Seattle, WA). In view of incredible simplicity and extremely low cost to test Coca's claims, at least, in incurables of high pain such as migraine and of high M&M and cost such as hypertension, the question:"Why isn't it tried?" is asked by skeptics from all walks of life (including the vast majority of mainstream practicing clinicians).
Cancer and AA
Vale of Leven and Mayo Clinic Studies
Cameron and Pauling reported a prolongation of survival over 4.2 times as great in 100 untreatable cancer patients given AA 10 g/day until death when compared to a control group of 1000 patients matched for age, sex and disease.44 The Mayo Clinic did two studies that were purported to test the validity of the Cameron/Pauling AA modality. Pauling has summarized the results of both studies integrated with much related material in his book (Ch.19, p.234), the source of the details in this paragraph. Pauling states that the Mayo Clinic trials were not equivalent to Vale of Leven and that the results of the second Mayo trial (published in a leading journal) were misrepresented to the American people by a number of high placed authorities in mainstream medicine as proof "that vitamin C has no value against advanced cancer and recommended that no more studies of vitamin C be made". Inter alia, Pauling also states that the Mayo patients did not receive AA continually until death, but for only a short time (median 2.5 months) and that none of them died while taking it, but they were studied for 2 more years and had not received any AA for a long time (median 10.5 months!) at death but these incredible discrepancies were not revealed to the public. In the rest of Chapter 19 and elsewhere throughout the book, Pauling argues that large numbers of deaths result from the facts that both physicians and the public were convinced by the widely publicized incorrect and misleading statements of the authorities that multigram AA has no value in cancer or most other diseases.
If high AA and aggressive glycemic control are not adopted, patients have greatly reduced probability of achieving tumor free remission (see Glycemic Control above). Virtually all conventional tumor reduction modalities involve stress, pain, or toxicity which can rapidly deplete buffy coat (WBC) AA to scorbutic levels (in one day!), and cause hyperglycemia which makes it difficult to restore WBC AA.
Cervical Cancer/Dysplasia, AA and Folate
Cervical dysplasia progressing to cancer results in disfiguring surgery, much other morbidity, death and high medical care costs. It was reported that the mean concentration of "vitamin C" in plasma was significantly lower in 46 cases with dysplasia than in 34 controls (0.36 vs 0.75 mg/dL, p<0.0001). The authors suggested a clinical trial with "vitamin C". From a separate university, Orr et al reported significantly lowered levels of plasma folate, vitamin A and "vitamin C" in a study of 78 patients with untreated cancer of the uterine cervix and stated the possible value of these vitamins for prevention and treatment requires investigation.46 Since all gynecologists read Am J Obstet Gynecol, how could these findings be ignored? The unequivocal (but false) declarations by high placed medical "authorities" (indicted by Pauling) that AA and other vitamins are without value in cancer, etc would seem to explain this inexcusable neglect. Cathcart routinely eliminates cervical dysplasia with AA ~10 g/d and 10 mg folate/d, as do some other physicians known to us.
Anomalies, AA and Glycemia
Although fetal malformations occur in ~60,000 US births per year and are strongly correlated with maternal glycemic level in early pregnancy, it has been shown that even diabetic mothers are spared this tragedy, as well as an associated fecundity defect, by strong glycemic control. It was suggested that the hyperglycemia-associated birth defects are actually due to low maternal and, hence, low fetal intracellular AA, all caused by maternal hyperglycemia. It is well known that mitosis requires high intracellular AA for the HMP shunt, to provide ribose. Hyperglycemia always decreases intracellular AA by competitively inhibiting the insulin mediated active transport of AA into cells. In non-diseased humans, the highest AA concentrations in all tissues occur in the fetus and decrease with human age (p.78). Therefore, the newborn must avidly absorb AA from the mother both as a fetus during gestation and in postpartum nursing. It has long been known that women who do not supplement AA show a dangerous fall in plasma AA from about 1.0 mg/dL to ~0.35 mg/dL at parturition, levels associated with serious diseases or death in the newborn. The predicted effects of glycemic level and AA were strongly supported by experiments in an animal model. Yet, for early pregnancy, glycemic control is not stressed and adequate supplementation of AA is condemned (as a cause of abortions, etc) today by "authorities" (p.358). Klenner reported that, in a series of 300 pregnancies, the gravidae were given AA, 4 g/d in the first trimester, 6 g/d in the second and 10 g/d in the third. All the infants were robust and there were none of the "normal" complications of pregnancy frequently encountered when little or no AA is supplemented. Klenner was able by this AA method to carry women through successful pregnancies who had aborted all previous attempts under their obstetricians.
Aging and AA
Glycation has been shown to be an important aging mechanism. In experiments on glycemic modulation of tumor tolerance in mice given supplemental AA, a marked depression of glycation of hemoglobin (~ 40%) was observed (Ely unpublished). This dose dependent effect was also found in the GHb (glycated hemoglobin) data of 600 humans on whom both blood chemistries and diet questionnaires including the amounts of supplemental AA habitually taken (at their election) were available. The implications of these findings re AA and aging are far reaching; they were announced at a meeting.
Morbidity, Refined Carbohydrate Intake and AA
The primitive (unrefined) diets on which most humans evolved contained no pure sugars and no other refined (or rapidly hydrolyzable) carbohydrates (rCHO), ie, zero "empty calories". High sugar foods such as berries, sugar cane, honey, etc, have high nutrient contents and were seasonal or rare. It is established that: (1) habitual consumption of rCHO raises both fasting and postprandial blood glucose levels in a dose dependent way; (2) elevated glucose competitively inhibits insulin mediated active transport of AA into WBC against the ~50:1 concentration gradient; (3) lower WBC AA causes the HMP shunt to slow decreasing resistance to infections and cancer; and (4) on a diet with half the calories from sugar some normal humans suffer serious endocrinological derangement with cortisol elevated to 3 times normal, etc. An important study by Cheraskin and Ringsdorf puts all of the these facts in perspective.7 They cite USDA statistics that, in 1970, the average American consumed 264 pounds of empty calories. On a dry weight basis, this was just over 50% of food intake. Using the Cornell Medical Index Health Questionnaire (CMIHQ) and a sample of 715 well educated people, they created plots of rCHO intake vs health problems. Extrapolations of these plots show that zero health problems occur at zero rCHO intake. Consider the implication for staggering increases in M&M and dollars that have been caused by rejection of the glycemic control (via the unrefined diet) modality.[23,35]
Mortality and AA Intake
Analysis of death rates from six principal causes in England and Wales, and their correlations with 13 nutrients from the National Food Survey was reported by the University of Birmingham. "Vit C" had the highest negative correlation (-0.63) with the sum of all causes and was negatively correlated with the individual diseases although the correlation became quite low, as is expected, in diseases where blood sugar is high (ie, -0.19 in diabetes). How could US "authorities" dispute the value of AA in view of this publication in the third largest circulation journal in the world?
Cold and AA
Although most of the large scale clinical trials of AA and the common cold done in the 1960's era showed some significant reduction in frequency and or duration of colds, the results were disappointing to Pauling and this author and a small number of others who are able to eliminate colds completely by 1 or more grams AA/day. These people are those who avoid sugar and have low values of plasma glucose (fasting and postprandial). This author during his first three decades had a high sugar intake and suffered several colds/yr. By chance, in his early thirties, he stopped eating sugar and (influenced by Klenner) started taking 1 g AA/d. He had only two colds in the next two decades, each one after a rare sugar gluttony. In a telecon, in 1972 Pauling stated he had studiously avoided sugar for many years prior to taking AA at the suggestion of Irwin Stone in about 1966. If the US per capita sugar consumption had been ~0 instead of over 100 lbs per year, the cold trials would have completely protected almost all of those given a gram or more of AA/d because of the resulting HMP stimulation at low blood sugar, as explained above. And, all white blood cells are enabled to be effective against disease by the HMP shunt which runs at a rate proportional to the the intracellular AA concentration.[13,21] The cold trials should be repeated using subjects who have not been taking AA; each subject would have glycated hemoglobin (GHb) measured by a finger stick and be assigned to the 5 quintiles according to GHb. Then, members of each of these quintiles are randomly assigned to the AA treatment or placebo control groups. It is predicted that when the trial is concluded in 1 or 2 years, the reduction in incidence of colds will be found to be essentially zero in the highest GHb quintile and essentially 100% in the lowest quintile.
Infectious Diseases and AA
In addition to the common cold, other viral and numerous bacterial diseases can be treated successfully by AA po (per os, or oral). Although Klenner used AA (ascorbic acid po, but sodium ascorbate in IV) to treat measles, mumps, chicken pox, adenovirus, herpes, etc, he felt that its greatest value in viral disease was against the polio virus.[18,54] All 60 polio patients in the 1948 epidemic recovered within 72 hrs with no residuals.18 For a period of 26 years, using the same regimen, all encephalitis patients recovered completely within 72 hrs. Klenner states that in such crises, the minimum dose is 350 mg/kg body weight to be repeated every hour for 6 -12 times depending on clinical improvement, then every 2-4 hours until the patient has recovered. Large doses of IV AA have a striking influence on mononucleosis. Cathcart uses AA po >150 g/d for this disease. Cathcart also cures influenza and induces prompt remission in herpes infections (cold sores, genital lesions and shingles) with bowel tolerance AA. Both Klenner's and Cathcart's acute infectious hepatitis patients are cured in a few days with massive doses of AA. Patients are well and back to work in 3-7 days and lab tests including SGOT, SGPT and bilirubins rapidly normalize. Baetgen used AA 10 g/d to cure hepatitis. Morishige and Murata have demonstrated the effectiveness of AA in preventing hepatitis from blood transfusions. Although AA may not cure chronic hepatitis, ~10 g AA/d plus other nutrients can indefinitely control disease, preventing liver necrosis and progression to hepatoma, transplant, etc (Cathcart pvt commun).
Treatment of bacterial infections also benefit from AA. Klenner reported diphtheria, hemolytic streptococcus and staphylococcus infections clearing within hours following AA given IV with │a 20G needle as fast as the patient╣s cardiovascular system would allow▓ (500-700 mg/kg body weight). When bacterial infections are treated with the appropriate antibiotic and AA, the effect is synergistic and patients respond rapidly, even if the bacterium is antibiotic resistant. Anyone who considers the use of AA can benefit from Cathcart's writings which include much clinical wisdom, not the least of which is his explicitly stated regret that people think of AA as a vitamin (which we have seen it is not).
The HMP shunt rate has been shown to increase by ~700% at plasma AA 140 mg/dL (200 times normal!). Such high levels are attainable in humans only by IV ascorbate (often called IVC) combined with continued oral intake. This protocol has been used by Cathcart in all infections including AIDS patients (brought under control but not cured by AA). He starts with often well over 50 g/d to bring the disease "under control" and tapering down to as low as 10 g/d as a maintenance dose in some cases. Notice that (the very expensive) interferon enhances CMI, but it has been reported for 20 years that AA very inexpensively doubles interferon production wherever virion replication is in progress.[25,26] Elevated interferon not only inhibits virion replication of an existing infection, but renders the host very resistant to infection by a second (possibly more deadly) virus. As long suspected14, the results of HIV studies may be "polluted" because most AIDS patients have found the value of AA and use it unknown to their physicians (who they fear would forbid it, asserting it is without value).
In summary, it appears that most bacterial infections and all acute viral infections treated by Klenner and Cathcart can be rapidly put in remission by high AA. It seems likely that Ebola, hanta and other highly lethal virus infections might also be treatable and preventable by this modality. The intellectual paralysis induced by the incompetents identified by Pauling makes the whole world suffer deadly epidemics, even polio, and deaths in virology labs. Now, since another ignored analog. But, why rapidly cure one million HIV+ patients for $100 apiece, if ~$20 billion/year is being spent on their care?
In the US where the refined diet prevails and most MD's are constrained to use the ineffective treatments of choice, the shocking annual toll from infections is: nearly 200,000 premature deaths (over 2 million years of life lost before age 65), over 42 million hospital days, cost over $17 billion, etc.
Surgery and AA
Klenner (p.74, etc)20 cites references from 1937 onward[60,61], that it was known that post operative AA was necessary for healing wound tensile strength, resistance to infection and elimination of most post-operative deaths. Klenner (p.74) found that without post-operative AA, by 6 hours, the plasma AA fell 1/4; by 12 hours was down to 1/2; and at 24 hours was 3/4 lower than at surgery. Klenner (p.74) encouraged patients to take oral AA 10 g/d for weeks prior to elective surgery and suggested surgeons use AA freely in fluids. His clinical wisdom is apparent in an example demonstrating the safety and efficacy of high AA doses in an "incurable" case: he had assisted on an abdominal exploratory surgery for an apparently scorbutic patient with numerous intestinal adhesions of her friable tissue. After repairing ~20 tears, the surgeon closed the cavity as hopeless. In post-operative care Klenner gave the patient 2 g AA every 2 hours for 2 days, and then 4 times/day; the patient was ambulatory in 36 hours, was discharged well in 7 days and outlived the surgeon by many years. What is the annual cost in M&M and dollars of poorly healed and infected wounds for mainstream's failure to evaluate Klenner's findings that are known by orthomolecular physicians to be valid?
Intoxications and AA
Intoxications from many causes are successfully treated with AA. Many thousands of needless deaths occur each year from the bites of snakes, spiders, flying insects and caterpillars. Klenner obtained rapid reversal of the swelling, pain, breathing difficulties, shock, etc, resulting from such "bites" using IVAA (350 to 710 mg/kg body weight) and AA po as followup. The release of histamine, which is a major shock producing substance, is minimized by AA. Similarly, Klenner normalized the shock in patients with barbiturate poisoning using 12 - 75 g IVAA.
¨¨¨The value of AA for chemical intoxications is also emphasized by Stone. AA protects against the effects of poisonous metals (e.g., mercury, lead, arsenic, etc), organic chemicals including bacterial and plant toxins, as well as addictive drugs. In a pilot study of 30 heroin addicts given 25 to 85 g sodium ascorbate/day (along with high doses of multivitamins, essential minerals and protein), the appetite returned, restful sleep was restored and mental alertness improved in 2 or 3 days. Moreover, there were no withdrawal symptoms. After 4 to 6 days, the AA dosage can be reduced to maintenance levels. AA can also be a life-saving measure for drug overdosage. Why aren't these effective and inexpensive methods being studied and used? ¨¨¨
Other Modern Germ Theory "Analogs"
Coenzyme CoQ10: A Rejected Modality
For background and striking results reported with CoQ10 in aging, cancer, heart disease, stroke, etc, read Physicians' Update. In 1997, a survey could not find MD's (even cardiologists!) at major US medical centers who were aware of CoQ10 (all were content with statins and surgery) although this miraculous molecule had been used in Japan for 30 years. Another specific example of mainstream ignoring its own highest expert at a cost of possibly millions of lives and trillions of dollars is found in the 1990 warning by Karl Folkers. This frequently honored chemist who first determined the structure of CoQ10 in 1958 and was Director of Research for Merck for 20 years, warned that heart disease is caused or worsened by the depression of CoQ10 that is associated with statin use and that CoQ10 should be supplemented in patients given statins63. A review of the literature on toxic effects of depressing CoQ10 suggests, inter alia, increased susceptibility to stroke injury (a leading cause of M&M) since the only agent found to protect significantly in stroke in decades of work on three animal models and a few human strokes64 is CoQ10. Internationally, as of 1995, there had been at least nine placebo controlled studies on the treatment of heart disease with CoQ10, a number were very large scale, the largest having 2664 patients. All confirmed the remarkable safety and efficacy of CoQ10. Recent studies claiming to show lack of efficacy of CoQ10 appear flawed (low dose, short time, untreatable patients, etc) in the light of world findings. Is this action designed to oppose acceptance of the low cost (unprofitable), non-toxic (endogenous), versatile CoQ10 modality (which, with vitamin E, could replace statins, and much else), just as the Mayo cancer "trials" authorities doomed AA?
Vitamin E: Another Rejected Modality
Several of the many benefits of high E intake have been discussed above. For better accounts with many references re E's numerous values, as published in leading journals, from 1950 on, by world respected clinicians (ie, Ochsner, Haeger, etc), and its arbitrary insulting rejection by the "authorities", see Pauling1 and Shute. It is surprising that E, second only to CoQ10 among available antioxidants, known for ~50 years could be termed "worthless" by a nutritionist. It is well known that: (1) cholesterol is not a risk factor for CVD unless LDL is oxidized; and (2) this is simply prevented by VITAMIN E[65,66]. In the late 1940's, the Shutes were able to show striking beneficial effects in CVD and other patients by 300 IU E/d. They were also able to conclude that loss of E in food processing to produce the US refined diet was a most probable cause of the appearance and growth of CVD as the largest producer of These matters are known to every capable student of nutrition. Until recent CoQ10 stroke findings, Shute's E therapies were the only or best available for CVD, rheumatic fever, stroke, etc.
Note added in proof: PubMed abounds with reports of the beneficial effects of caloric restriction on a variety of diseases including cancer, the mechanism of which (the authors state) is unknown. We have shown in humans and animals that in breast cancer[23,24] and birth defects[47,50] even modest glucose elevation competitively inhibits insulin-mediated active transport of AA into WBC depressing the HMP shunt, CMI, mitosis, etc.
Support from Applied Research Institute and many valuable comments and help with the literature by Dr. Cheryl Krone of the Institute are gratefully acknowledged.
AA= ascorbic acid, ascorbate
CMI= cell mediated immunity
CVD= cardiovascular disease
GHb= glycated hemoglobin
g/d= grams per day
HMP= hexose monophosphate
IVC= intravenous ascorbate
M&M= morbidity and mortality
mg%= mg/dL = mg/.1Liter
CoQ10= coenzyme Q10
RBC= red blood cells or erythrocytes
rCHO= refined carbohydrate
WBC= white blood cells
1. Pauling LJ: How to live longer and feel better. New York, Avon Books, 1987; 413.
2. Klenner FR: Significance of high daily intake of ascorbic acid in preventive medicine. J Prev Med, 1974; Spring: 45-69.
3. Shute WE: Dr Wilfred Shute's complete updated vitamin E book. New Canaan CT. Keats Publish. 1975; 255.
4. Coca AF: The Pulse Test. New York. Arco. 1956; 189.
5. Hoffer A: Ascorbic acid and toxicity. New Engl J Med, 1971; 285: 635-636.
6. Hoffer A: Clinical procedures in treating terminally ill cancer patients with vitamin C. J Orthomol Med, 1991; 6: 155-160.
7. Cheraskin E, Ringsdorf WM Jr: How much refined carbohydrate should we eat? Am Lab, July 1974; 6: 31-35.
8. Langsjoen, PH: Introduction to Coenzyme Q10, 1995. On Univ of Wash web site http://faculty.washington.edu/ely
9. Yudkin J: Sweet and Dangerous. New York. Bantam Books, Inc. 1972; 107-112.
10. Stone I: The Healing Factor. Vitamin C against disease. New York. Grosset & Dunlap. 1972; 152-162.
11. Chatterjee IB: Evolution and the biosynthesis of ascorbic acid. Science, 1973; 182: 1271-1272.
12. Lewin S: Vitamin C. Its Molecular Biology and Medical Potential. New York Academic Press. 1976; 231.
13. Cooper MR, McCall CE, DeChatelet LR: Stimulation of leukocyte hexose monophosphate shunt activity by ascorbic acid. Infect Immun, 1971; 3: 851-853.
14. Cathcart RF: Vitamin C in the treatment of acquired immune deficiency syndrome (AIDS). Med Hypotheses, Aug 1984; 14(4): 423-433.
15. Cathcart RF: Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy. Medical Hypotheses, 1981; 7: 1359-1376.
16. Luberoff BJ: Symptomectomy with vitamin C: A chat with Robert Cathcart, MD. ChemTech, 1978; 8(2): 78-88.
17. Denson KW, Bowers EF: The determination of ascorbic acid in white blood cells. Clin Sci, 1961; 21: 157-62.
18. Klenner FR: The treatment of poliomyelitis and other virus diseases with vitamin C. Southern Med Surg, 1949; III: 209-214.
19. Klenner FR: Massive doses of vitamin C and the virus diseases. South Med and Surg, 1951; 103: 101-107.
20. Klenner FR: Observations on the dose and administration of ascorbic acid when employed beyond the range of a vitamin in human pathology. J Appl Nutr, 1971; 23: 61-88.
21. Yonemoto RH: Vitamin C and immune responses in normal controls and cancer patients. Int J Vit Nutr Res, 1979; 19: 143-154.
22. Yonemoto RH, Chretien PB, Fehniger TF: Enhanced lymphocyte blastogenesis by oral ascorbic acid. Proc Amer Assoc Canc Res, 1976; 17: 288.
23. Ely JTA: Glycemic Modulation of Tumor Tolerance. J Orthomol Med, 1996; 11(1): 23-34.
24. Santisteban GA, Ely JTA, Hamel EE, et al.: Glycemic modulation of tumor tolerance in a mouse model of breast cancer, Biochem Biophys Res Commun, 1985; 132(3): 1174-9.
25. Siegel BV: Enhanced interferon response to murine leukemia virus by ascorbic acid. Infect and Immun, Aug 1974; 10: 409-410.
26. Siegel BV, Morton JI: Vitamin C and the immune response. Experientia, 1977; 33: 393-395.
27. Hume R, Weyers W, Rowan T et al: Leucocyte ascorbic acid levels after acute myocardial infarction. Brit Heart J, 1972; 34: 238-243.
28. Machlin LJ: Use and safety of elevated dosages of vitamin E in adults. Int J Vitam Nutr Res Suppl, 1989; 30: 56-68.
29. Campbell G, Steinberg M, Bower D: Ascorbic acid-induced haemolysis in G-6-PD deficiency. Ann Intern Med, 1975; 82: 810.
30. Mehta JB, Singhal SB, Mehta BC: Ascorbic-acid-induced haemolysis in G-6-PD deficiency. Lancet, 1990; 336: 944.
31. Rees DC, Kelsey H, Richards JDM: Acute haemolysis induced in high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. Brit Med J, 1993; 306: 841-842.
32. Gordon H, De Metry JP: Hemolysis in hydrogen peroxide of erythrocytes of premature infants: Effect of alpha-tocopherol. Proc Soc Exper Biol & Med, 1952; 79: 446.
33. Chen LH: An increase in vitamin E requirement induced by high supplementation of vitamin C in rats. Am J Clin Nutr, 1981; 34: 1036-1041.
34. Koroljow S: Insulin coma therapy. Psychiatric Quarterly, 1962: 36: 261-70.
35. Ely JTA: Unrecognized pandemic subclinical diabetes of the affluent nations: causes, cost and prevention. J Orthomolecular Med, 1996; 11(2): 95-99.
36. Glicksman AS, Myers WPL, Rawson RW: Diabetes mellitus and carbohydrate metabolism in patients with cancer. Med Clin North Am, 1956; 40: 887-900.
37. Schroeder HA: The Trace Elements and Man. Old Greenwich CT. Devin-Adair Co. 1973.
38. Dugal LP, Fortier G: Ascorbic acid and acclimatization to cold in monkeys. J Appl Physiol, 1952; 5: 143-146.
39. Smolyanski BL: Effect of ascorbic acid on functional state of adrenal cortex in elderly persons. Fed Proc 1963; 22: T1173-1176.
40. Dawson W, West GB: The influence of ascorbic acid on histamine metabolism in guinea pigs. Brit J Pharmacol, 1965; 24: 725-734.
41. Selye H: The Stress of Life. New York, McGraw-Hill. 1956.
42. Bicknell F, Prescott F: The Vitamins in Medicine. Milwaukee. Lee Foundation for Nutritional Research. 1953.
43. Anonymous. Ascorbic acid levels of blood and urine in patients with allergic rhinitis. Editorial. Eye Ear Nose Throat Monthly, 1968; 47(7): 326-7.
44. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival time in terminal human cancer. Proc Natl Acad Sci USA, 1976; 73: 3685-3689.
45. Romney SL, Duttagupta C, Basu J, et al: Plasma vitamin C and uterine cervical dysplasia. Am J Obstet Gynecol, 1985; 151 976-980.
46. Orr JW Jr, Wilson K, Bodiford C, et al: Nutritional status of patients with untreated cervical cancer. II. vitamin assessment. Am J Obstet Gynecol, 1985; 151 632-635.
47. Miller E, Hare JW, Cloherty JP, et al: Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981; 304: 1331-1334.
48. Ely JTA: Hyperglycemia and major congenital anomalies. New Engl J Med, 1981; 305(14), 833.
49. Javert C, Stander HJ: Plasma vitamin C and prothrombin concentration in pregnancy. Surgery, Gynecol and Obstet,1943; 76: 115-122.
50. Hamel EE, Santisteban GA, Ely JTA, et al: Hyperglycemia and reproductive defects in non-diabetic gravidas: a mouse model test of a new theory. Life Sci, 1986; 39: 1425-1428.
51. Cerami A, Vlassare H, Brownlee M: Glucose and aging. Scientific American, 1987; 256(5): 90-96.
52. Ely JTA, Warner GA, Read DH, et al: Protein glycation: ascorbate antagonism (abstract). Bull APS (Div of Biol Phys), 1988; 33(3): 296.
53. Knox EG: Ischaemic-Heart-Disease mortality and dietary intake of calcium. The Lancet, 1973; 1: 1465-1467.
54. Klenner FR: Masive doses of vitamin C and the virus diseases. J Appl Nutr, 1958; 11(1): 49-57.
55. Baetgen D: Results of treating epidemic hepatitis with high dose ascorbic acid. Mediz Monatschr, 1961; 15: 30-36.
56. Morishige F, Murata A: Vitamin C for prophylaxis of viral hepatitis B in transfused patients. J Intl Acad Prev Med, 1979; 5: 54-8.
58. Fudenberg HH: AIDS Research. The Scientist, 1997; 11(4): 13.
59. Pizza G, Chiodo F, Colangeli V, et al: Preliminary observations using HIV-specific transfer factor in AIDS. Biotherapy, 1996; 9(1-3): 41-7.
60. Bartlett MK, Jones FM, Ryan AE: Vitamin C and wound healing: ascorbic acid content and tensile strength of healing wounds in human being. New Engl J Med, 1942; 226: 474-481.
61. Crandon JH, Landau B, Mikal S, et al: Ascorbic acid economy in surgical patients as indicated by blood ascorbic acid levels. New Engl J Med, 1958; 258: 105-113.
62. Libby AF, Stone I: The hyposacorbemia-kwashiorkor approach to drug addiction therapy. A pilot study. J Orthomolecular Psychiatry, 1977; 6 (4): 300-308.
63. Folkers K, Langsjoen P, Willis R, et al: Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA, 1990; 87: 8931-8934.
64. Ely JTA, Fudenberg HH, Bliznakov EG, Branch JD: Hemorrhagic Stroke in Human Pretreated with Coenzyme Q10: Exceptional Recovery as Seen in Animal Models. J Orthomol Med, 1998; 13(2): 105-109.
65. Gey KF, Puska P, Jordan P, Moser U: Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr, 1991; 53:326s-334s.
66. Esterbauer H, Dieber-Rothender M Striegl G, et al: Role of vitamin E in preventing oxidation of low-density lipoprotein. Am J Clin Nutr, 1991; 53: 314s-321s. 67. Feltman J, ed: Prevention's Giant Book of Health Facts, Rodale Press, Emmaus, PA, 1991; 352.
68. Zhu Z, Haegele A, Thompson H: Effect of caloric restriction on pre-malignant and malignant stages of mammary carcinogenesis. Carcinogenesis, 1997; 18(5):1007-1012.
It is gratifying to report the first observation of the amelioration of effort angina by the use of high-dose L-lysine and ascorbate in a man with severe coronary artery disease (CAD). This regimen was based on the hypothesis that, in thrombotic atherosclerosis, lipoprotein(a) [Lp(a)]ő size-heterogeneous, LDL- like particles d displaying independent risk activity for CAD őinitiates plaque formation by binding to fibrin in the damaged arterial wall. This postulated mechanism correlates with the findings that apoliprotein(a) [apo(a)] has a striking homology to plasminogen and the Lp(a) accumulates in atherosclerotic lesions in the arteries of man (Rath et al., 1989)and the hypoascorbic guinea pig (Rath and Pauling, 1990a, 1990b) and in occluded bypass venous grafts (Cushing et al., 1989). It is hoped that the remarkable outcome in this single case will motivate clinicians to examine the efficacy of lysine and ascorbate in additional cases of refractory angina.
Coronary Heart Disease
In late April 1991, a biochemist National Science Medalist* with a familial trait of CAD told me that he experiences effort angina, in spite of medication and three coronary bypass operations. His father and a brother both died of CAD at age 62 he had his first angina attack at age 38. Now aged 71, this biochemist has fought CAD also by reducing risk factors (i.e., not smoking, exercising moderately, and diet/ weight controlő134 Ibs. at 5'5"). His first operation in 1978 (two vein grafts and one LIMA graft) precipitated a second operation (a parallel vein graft) five months later. Stripping of saphenous veins in the first operation induced massive swelling, thrombi, and infection in his leg; bilateral pulmonary emboli; and loss of patency in a vein graft. In 1987, following an attack of unstable angina, he was hospitalized for coronary angiography, adjustment of medications, and a Tl-stress test. A third operation in April 1990 followed attacks of unstable angina, a small MI, and angiography that revealed total occlusion of his right coronary artery and all bypass grafts except for a patent LIMA graft. Unfortunately, this LIMA was lacerated while freeing dense adhesions early in the third operation and required urgent heart-lung bypass cannulation and vein-patch repair; additionally, three venous grafts were made to left coronary arteries. The operation, which diminished but did not eliminate effort angina, left him with 1.8 liters of left-sided pleural effusate that was resistant to diuretics and tapping, and took 10 months to resorb. Medication with beta-receptor and calcium-channel blockers and lovastatin was reinstated; also, 325 mg of aspirin given initially was reduced to 81 mg following bilateral eye hemorrhages and adhesions that impair his peripheral vision. To this medication, he added 6 g of ascorbate (acid form), 60 mg CoQ-10; a multivitamin tablet with minerals; additional vitamins A, E and a B-complex; lecithin; and niacin, on advice of his cardiologist to try to raise his HDL level. Nevertheless, he still had to take nitroglycerin sublingually to suppress angina during a daily two mile walk and when working in his yard. This effort angina continued to worsen, imparting a feeling of impending doom that was reinforced by his cardiologist's admonition during a check-up in March 1991 that a fifth angiographic test and a fourth bypass operation were no longer options. Also, the saphenous veins from his groin regions and legs had all been used for previous grafts.
Effect of the Addition of Lysine
In this predicament and with his history of restenosis, I suggested that he continue ascorbate and add 5 g of L-lysine daily (ca., six times the lysine derived from dietary protein) to try to mitigate the atherosclerotic acitivity of Lp(a). After reading the 1990 Rath and Pauling reports and their manuscript titled "Solution to the puzzle of human cardiovascular disease", he began taking I g of lysine in early May 1991 and reached 5 g (in divided doses eight hours apart) by mid-June. In mid-July, his HDL was, as usual, a low 28 mg/dl. A low-normal 0.9 mg/dl blood creatinine indicated that lysine could be increased, if needed. He could now walk the same two miles and do yard work without angina pain and wrote, "the effect of the lysine borders on the miraculous". By late August, he cut up a tree with a chain saw, and in early September started painting his house. By late September, possibly from over-exertion, he again began to have angina symptoms during his walks, but after stopping strenuous work and increasing lysine to 6 g [calculated to provide a peak 280,000 molar excess in the blood over his then 6 mg/dl of Lp(a) to help compensate for the relatively high dissociation constant of lysine-Lp(a)] these symptoms stopped entirely by mid-October. His blood creatinine was still a normal 1.2 mg/dl. He attributes his newfound wellbeing to the addition of lysine to his other medications and vitamins. His wife and friends comment on his renewed vigor.
This severe case of restenosing CAD was a difficult challenge to try to ameliorate by the addition of lysine. While a positive effect was anticipated, lysine had not been tested for activity in inhibiting or reversing Lp(a)-laden atherosclerotic plaques in hypoascorbemic guinea pigs (Rath and Pauling, 1990b). However, it was known that Lp(a) binds to lysine-Sepharose, immobilized fibrin and fibrinogen (Harpel et al., 1989); and the epithelial-cell receptor for plasminogen ( Gonzalez-Gronow et al., 1989). This binding specificity correlates with the genetic linkage on chromosome six and striking homology of apo(a) and plasminogenőhighly conserved multiple kringle-four domains, a kringle-five domain, and a protease domain (McLean et al., 1987). Moreover, using the molecular evolutionary clock, the loss in primates of the ability to synthesize ascorbate (Zuckerkandl and Pauling, 1962; Rath and Pauling, 1990a) and acquisition of Lp(a) (Maeda et al., 1983) both appear to have occurred about 40 million years ago. These observations and the presence of Lp(a) in sclerotic arteries (Rath et al., 1989; Rath and Pauling, 1990b) and in venous grafts (Cushing et al., 1989) indicate that atherosclerosis may be initiated by excess binding of Lp(a) to fibrin in vascular wall clots, thus interfering with normal fibrinolysis by plasmin. This thrombogenic activity, which is postulated to reside in plasmin-homologous domains of Lp(a), may help to stabilize the damaged vascular wall, especially in ascorbate deficiency (Scanu, Lawn, and Berg, 1991; Rath and Pauling, 1990a). Once bound to fibrin, the LDL-like domain of Lp(a) could promote atheromas (Scanu, Lawn, and Berg, 1991). In this scenario, high-dosage lysine could inhibit or reverse plaque accretion by binding to Lp(a). Independently, lysine benefits the heart as a precursor with methionine in the synthesis of L-carnitine, the molecule that carries fat into mitochondria for the synthesis of adenosine triphosphate (ATP) bond energy needed for muscular and other cellular activities (Cederblad and Linstedt, 1976). While his intake of 60 mg of CoQ-10, also required for ATP synthesis, prior to the addition of lysine improved his sense of wellbeing, it did not suppress his angina. Ascorbate without lysine also did not ameliorate angina, but it is needed as an antioxidant to protect the vascular wall against peroxidative damage and in hydroxylation reactions both in the synthesis of carnitine and in the conversion of procollagen to collagen (hydroxylation of prolyl and Iysyl residues) (Myllyla et al., 1984) to strengthen the extracellular matrix of the wall.
Whatever the pathomechanisms of atherosclerosis, the addition of lysine to medications and vitamins, including ascorbate, markedly suppressed angina pectoris in this intractable case of CAD. While a single case is anecdotal, it is hoped that its remarkable success will motivate clinicians to commence studies as soon as possible of the general applicability of lysine and ascorbate in relieving angina pectoris, so as to decrease greatly the amount of human suffering with less dependence on surgical intervention.
Footnote (p. 144) *The biochemist patient made a major contribution to this report, but wishes anonymity.
1. Cederblad G and Linstedt S: Metabolism of labeled carnitine in the rat. Archives of Biochemistry and Biophysics 175:173-182, 1976.
2. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM and Morrisett JD: Quantitation and localization of lipoprotein(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 9:593-603, 1989.
3. Gonzalez-Gronow M, Edelberg J M and Pizzo SV: Further characterization of the cellular plasminogen binding site: Evidence that plasminogen 2 and lipoprotein(a) compete for the same site. Biochemistry 28:2374-2377, 1989.
4. Harpel PC, Gordon BR and Parker TS: Plasminogen catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc. Natl. Acad. Sci. USA 86:3847-3851, 1989.
5. Maeda N, Bliska JB and Smithies O: Recombination and balanced chromosome polymorphism suggested by DNA sequences 5' to the human deltaglobin gene. Proc. Natl. Acad. Sci. USA 80:5012-5016, 1983.
6. McLean JW, Tomlinson JE, Kuang WJ et al.: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132-137, 1987.
7. Myllyla R, Majamaa K, Gunzler V, Hanuska-Abel HM and Kivirikko KI: Ascorbate is consumed stoichiometrically in the uncoupled reactions catalyzed by prolyl-4-hydroxylase and Iysyl hydroxylase. Journal of Biological Chemistry 259:5403-5405, 1984.
8. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ and Beisiegel U: Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9:579-592, 1989.
9. Rath M and Pauling L: Hypothesis: Lipoprotein(a) is a surrogate for ascorbate. Proc.. Natl. Acad. Sci. USA 87:6204-6207, 1990a.
10. Rath M and Pauling L: Immunological evidence for the accumulation of lipoprotein(a) in the atherosclerotic lesion of the hypoascorbemic guinea pig. Proc. Natl. Acad. Sci. USA 87:9388-9390, 1990b.
11. Scanu M, Lawn RM and Berg K: Lipoprotein(a) and atherosclerosis. Annals of Internal Medicine 115:209-218, 1991.
12.Zuckerkandl E and Pauling L: Molecular disease, evolution, and genic heterogeneity. In: Horizons in Biochemistry, eds. Kasha M. and Pullman B. (Academic Press, New York) pp. 189-225, 1962.
DEBUNKING THE VITAMIN C OR ASCORBIC ACID DANGER
As of this writing, we have traced the basis of the news report to Victor Herbert, Karl E. Herbert and British Researchers Ian Podmore and Joseph Lunec. We have written to Dr. Podmore asking for clarification of the findings reported in NATURE. We'll post any response when it becomes available. Until then it is unknown whether Joseph Lunec or Ian Podmore have drawn these surprising conclusions from their research, or whether others have possibly miss-interpreted the results of this six week study.
The study authors themselves have questioned the reliability of such DNA damage measurements in the past: The extraction of DNA prior to use of either of these methods is an area of much controversy as several workers have suggested that cell lysis and/or extraction with organic solvents can cause artefactual generation of 8-OHdG. One must therefore be careful in interpreting the results of such measurements on the grounds of a suitable method of extraction which does not generate in vitro artefact. [J. Lunec, Q. Zheng, M. Evans, K. Herbert. (Full citation below)] From the authors paper, we find that when the newer method was used for 8-OHdG, both vitamin E and C showed benefit, as oxidation damage decreased by 50%. (We have not yet be able to determine the method used to determine 8-OHdA, the result that sparked this health scare. Please note, measuring 8-OHdA was not mentioned in the study abstract as either an objective or priority.)
For the record, here are some concerns about the NATURE report.
The study was published as a letter to the editor to NATURE. According to this letter, the study was run in 1995, or earlier, so the first question is, why did a study run three years ago suddenly become major news, especially since they couldn't get their findings published in a peer-reviewed journal? And when were these measurements actually made? The result was a secondary finding. According to the study abstract we found on the internet: The aim of this study was to investigate the effect of vitamin C mg/day) and vitamin E (400 i.u./day) supplementation in normal individuals in terms of lymphocyte levels of the base-lesion 7, 8-di hydro 8-oxo-2-deoxyguanosine (8-oxoG)which is recognized as a specific marker of ROS induced damage, in vivo.
However, their conclusion states: Levels of 8-oxodG were unaffected by placebo, but were significantly reduced by approximately 50% by both vitamin C and vitamin E. The vitamin E measurements were omitted from the NATURE report. The DNA extraction methods the team employed (that seemed to show damage) are unknown, but since a new method was the purpose of the study (and the new method showed great benefit to vitamin C) we must assume the older method was measured for comparison. Only the comparison measurements showed damage. According to the author's earlier research, the newer methods are needed because the old methods may not be reliable. (As in all science, these results will have to be replicated by other researchers before they can be taken seriously.) It is uncertain how accurate any of these arcane "damage" measurements are. In other words, there may in-fact be no RNA/DNA damage what-so-ever. The researchers mention a strong "anti oxidant" affect of Vitamin C at the same time coupled with a profound "pro oxidant" affect. (Vitamin C is already known to have both these properties. Since this property was unknown to the authors, this property may have affected the experiment.) It does not make sense that a "6 week" study of low dose ascorbate in humans (several weeks on placebo) could isolate DNA/RNA damage to the vitamin C supplement. (Especially if turns out that the same "damage" could be caused by an extra onion or two on a hamburger...)Any theory of "Vitamin C causes DNA damage" must explain that lack of any clinical or epidemiological evidence in the great many people taking far greater amounts of vitamin C than the RDA. In fact, these study results, if born out, may call into question the value of these so-called "8-oxodA markers" that are "recognized as specific for free radical induced damage." One would hope that preliminary work in guinea pigs, one of the few species that does not make its own vitamin C, had been done before a story like this gets publicity. (Brody mentioned mice. Mice make their own vitamin C so any research with mice is useless.) There is nothing in the study that indicates 500 mg has any special significance -- other than that is the amount they chose to investigate. Yet, the Brody article makes 500 mg into a significant "finding." If a theory is postulated that vitamin C in large amounts causes "arthritis and cancer" then it would have to explain why this process does not appear to be present in animals. Most animals must obtain the various vitamins and minerals in their diet to survive. Vitamin C is an exception. Unlike humans, most animals make their own vitamin C in their bodies in very large amounts. This vitamin C, adjusted for body weight, averages 9,000 to 12,000 mg and goes directly into the blood stream. (We humans would have to ingest some 18,000 to 24,000 mg by mouth to get this much in our blood stream and tissues.) So why did this study get so much press? (That's what we'd like to know.)BOTTOM LINE: There isn't a single shred of hard evidence to back up the speculative health claims published by Jane Brody in the New York Times, i.e. that doses of Vitamin C above the RDA may be harmful in any way, shape or form. We doubt these results will be repeated, but even if they are and the known "pro-oxidant" property of Vitamin C is being measured by this experiment, it does not follow by logic that Vitamin C is harmful, nor would the serious postulated consequences necessarily follow. These fears are pure speculation. (There is no epidemiological or other evidence that high vitamin C plays a role in the formation of chronic disease. If fact, as we will begin to publish in MEGASCORBATE THERAPIES, a massive body of evidence exists that supports the opposite conclusion. That so-called high amounts of supplement ascorbate (Vitamin C) are in fact PROTECTIVE of these diseases.) Rhetorical Question: If vitamin D helps prevent breast cancer, and if cholesterol is required with sunlight to make vitamin D in our bodies (it is), then do cholesterol lowering drugs contribute to breast cancer? This is the same logic, by the way, that medicine uses to connect vitamin C to kidney stones, and now to arthritis and cancer. No experimental proof. Why is this logic appropriate in one argument, but not another? The fact that vitamin C has pro-oxidant as well as anti-oxidant properties is well known and not news. In 1986 Linus Pauling wrote in his book HOW TO LIVE LONGER AND FEEL BETTER in the chapter Vitamins in the Body: "The ways in which ascorbic acid (Vitamin C) functions in the human body relate first to the fact that it engages on both sides of the universal oxidation-reduction reaction that subtracts or adds hydrogen atoms to a molecule. (Vitamin C) is readily oxidized to dehydroascorbic acid by the surrender, to oxidizing agents, of the two hydrogen atoms... [shown in the figure] This action is readily reversible, for dehydroascorbic acid acts as a strong oxidizing agent, and by picking up two hydrogen atoms is reduced to ascorbic acid. It is likely that the reducing power of ascorbic acid and the oxidizing power of dehydroascorbic acid are responsible for some of the physiological properties of the substance." [PAULING, 1986]
It is strange how a conclusion of potential harm can be drawn from the Lunec, et. al. study without hard evidence of cause and effect, to say the least. Especially on the wings of the announcement that for the first time ever, the National Academy of Sciences is recommending that Americans take vitamin supplements. Speaking of wings, while airplanes have them, it does not mean that if it has wings, it is necessarily an airplane. Even if the oxidation "damage" that researcher Lunec studied are always present in cancer and arthritis patients, it does not follow that these markers are the cause of these diseases, nor can vitamin C be blamed if it too seems to create these oxidation markers in laboratory experiments. Our official response will be published here. While we wait to sort this story out, people worried about this report ought to keep our animal friends in mind. Like humans, most animals must obtain the various vitamins and minerals in their diet to survive. Vitamin C is an exception. Unlike humans, most animals make their own vitamin C in their bodies in very large amounts. This vitamin C, adjusted for body weight, averages 9,000 to 12,000 mg and goes directly into the blood stream. (We humans would have to ingest some 18,000 to 24,000 mg by mouth to get this much in our blood stream and tissues.) If a theory is postulated that vitamin C in large amounts causes "arthritis and cancer" then it would have to explain why this process does not appear to be present in animals.
Jane Brody of the New York times even quoted Lunec as saying on the basis of their findings it "would be unethical to test higher levels" of vitamin C on people. Coincidentally, the Foundation resubmitted our proposal on April 6, 1998 to the NIH to study high doses of vitamin C on heart disease. Maybe it isn't a coincidence. Stay tuned. According to Stephen Sheffrey, D. D. S., a strong pro-Vitamin C advocate: "The ongoing effort to discredit vitamin C began in the 1940s after it was shown to have anti viral and antitoxic properties. Certain members of the pharmaceutical-medical complex, after first promoting vitamin C as a treatment for fevers and infections, realized that widespread use of this non prescription substance would cancel the need for developing a lucrative prescription anti viral drug market.
For this reason, all the scientific trials which have not shown vitamin C to be of any benefit against viral attacks either shorted the recommended dose or altered the recommended treatment procedure. Anyone who knows the vitamin C has been blatantly discredited in this manner should be ashamed to speak of ethics in order to forestall a proper evaluation of the vitamin's therapeutic potential.
I wonder if [Lunec] can point to an increase in heart trouble along with an increase in vitamin C consumption. I believe that just the opposite has occurred." We consider the following AP article to be much more appropriate than Jane Brody's one sided articles from the New York Times syndicate. Following the AP report are some abstracts of papers written by Joseph Lunec, et. al